Drug Information

Drug General Information
Drug ID
D0E7IM
Former ID
DNCL002332
Drug Name
OPB-31121
Indication Hepatocellular carcinoma [ICD9: 155; ICD10:C22.0] Phase 1/2 [523569]
Company
Otsuka America Pharmaceutical
Target and Pathway
Target(s) Signal transducer and activator of transcription 3 Target Info Inhibitor [532231]
KEGG Pathway Chemokine signaling pathway
HIF-1 signaling pathway
FoxO signaling pathway
Signaling pathways regulating pluripotency of stem cells
Jak-STAT signaling pathway
Prolactin signaling pathway
Adipocytokine signaling pathway
Toxoplasmosis
Hepatitis C
Hepatitis B
Measles
Epstein-Barr virus infection
Pathways in cancer
Viral carcinogenesis
Proteoglycans in cancer
MicroRNAs in cancer
Pancreatic cancer
Acute myeloid leukemia
Inflammatory bowel disease (IBD)
PANTHER Pathway Angiogenesis
EGF receptor signaling pathway
Inflammation mediated by chemokine and cytokine signaling pathway
Interleukin signaling pathway
JAK/STAT signaling pathway
PDGF signaling pathway
Ras Pathway
CCKR signaling map ST
Pathway Interaction Database GMCSF-mediated signaling events
IL27-mediated signaling events
Signaling events mediated by PTP1B
IL12-mediated signaling events
Signaling events mediated by TCPTP
Signaling events mediated by HDAC Class I
IL2-mediated signaling events
CXCR4-mediated signaling events
EGF receptor (ErbB1) signaling pathway
IFN-gamma pathway
ErbB1 downstream signaling
ErbB2/ErbB3 signaling events
IL6-mediated signaling events
PDGFR-beta signaling pathway
Neurotrophic factor-mediated Trk receptor signaling
IL23-mediated signaling events
Signaling events mediated by Stem cell factor receptor (c-Kit)
FGF signaling pathway
RAC1 signaling pathway
Notch-mediated HES/HEY network
IL12 signaling mediated by STAT4
Reactome Interleukin-6 signaling
Senescence-Associated Secretory Phenotype (SASP)
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
Transcriptional regulation of pluripotent stem cells
Growth hormone receptor signaling
WikiPathways Serotonin Receptor 2 and STAT3 Signaling
Notch Signaling Pathway
Interferon type I signaling pathways
EPO Receptor Signaling
TGF Beta Signaling Pathway
IL-2 Signaling Pathway
EGF/EGFR Signaling Pathway
IL-4 Signaling Pathway
IL-6 signaling pathway
Signaling of Hepatocyte Growth Factor Receptor
Kit receptor signaling pathway
Nuclear Receptors Meta-Pathway
Estrogen Receptor Pathway
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
IL-3 Signaling Pathway
Dopaminergic Neurogenesis
Transcriptional regulation of pluripotent stem cells
Mammary gland development pathway - Involution (Stage 4 of 4)
Signaling by SCF-KIT
Interleukin-6 signaling
Growth hormone receptor signaling
JAK/STAT
PDGF Pathway
BDNF signaling pathway
Oncostatin M Signaling Pathway
Adipogenesis
Interleukin-11 Signaling Pathway
AGE/RAGE pathway
Prostate Cancer
TSLP Signaling Pathway
IL-9 Signaling Pathway
IL17 signaling pathway
IL-7 Signaling Pathway
Regulation of Microtubule Cytoskeleton
Leptin signaling pathway
TSH signaling pathway
Cell Differentiation - Index
Cell Differentiation - meta
Signaling by PDGF
NGF signalling via TRKA from the plasma membrane
TFs Regulate miRNAs related to cardiac hypertrophy
MicroRNAs in cardiomyocyte hypertrophy
Physiological and Pathological Hypertrophy of the Heart
Androgen receptor signaling pathway
IL-5 Signaling Pathway
References
Ref 523569ClinicalTrials.gov (NCT01406574) Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma. U.S. National Institutes of Health.
Ref 532231OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.